Enrichment of the lungs with oral commensal microbes was associated with advanced-stage disease, worse prognosis, and tumor progression in patients with lung cancer, according to results from a study published in Cancer Discovery, a journal of the American Association for Cancer Research.1
“The lungs were long thought to be sterile, but we now know that oral commensals—microbes normally found in the mouth—frequently enter the lungs due to unconscious aspirations,” said Leopoldo Segal, MD, Director of the Lung Microbiome Program, Associate Professor of Medicine at the New York University (NYU) Grossman School of Medicine, and a member of NYU Langone’s Perlmutter Cancer Center. Although many studies have demonstrated the impact of the gut microbiome on cancer, the impact of the lung microbiome on cancer remains unclear.
Leopoldo Segal, MD
Prior research from Dr. Segal and colleagues showed that the presence of microbes in the lung can activate the immune response, leading to the recruitment of immune cells and inflammatory proteins such as the cytokine interleukin-17 (IL-17), which has been shown to modulate lung cancer pathogenesis. “Given the known impact of IL-17 and inflammation on lung cancer, we were interested in determining if the enrichment of oral commensals in the lungs could drive an IL-17–type inflammation and influence lung cancer progression and prognosis,” Dr. Segal explained.
In this study, Dr. Segal and colleagues analyzed the lung microbiomes of 83 untreated adult patients with lung cancer using samples obtained from diagnostic clinical bronchoscopies. Samples were analyzed to identify microbial composition and to determine which genes were expressed in lung tissue.
The researchers found that patients who had advanced-stage lung cancer (stages IIIb–IV) had greater enrichment of oral commensals in the lungs than those who had early-stage disease (stages I–IIIa). Furthermore, the enrichment of oral commensals in the lungs was associated with decreased survival, even after adjusting for tumor stage. Poor prognosis was associated with the enrichment of -Veillonella, Prevotella, and Streptococcus bacteria in the lung microbiome, and tumor progression was associated with the enrichment of Veillonella, Prevotella, Streptococcus, and Rothia bacteria.
In patients with early-stage disease, enrichment of Veillonella, Prevotella, and Streptococcus was associated with activation of the p53, PI3K/PTEN, ERK, and IL-6/IL-8 signaling pathways. A Veillonella strain, found to be enriched in patients with advanced-stage lung cancer, was associated with the expression of IL-17, cell adhesion molecules, cytokines, and growth factors, as well as with the activation of the TNF, PI3K-AKT, and JAK-STAT signaling pathways.
Dr. Segal and colleagues also examined the effects of the lung microbiome in a mouse model of lung cancer. They seeded Veillonella parvula in the lungs of mice with lung cancer to model the enrichment of oral commensals. This led to decreased survival, weight loss, and increased tumor burden and was associated with increased expression of IL-17 and other inflammatory proteins, increased recruitment of immune-suppressing cells, and increased activation of inflammatory pathways. To understand the role of IL-17 in lung cancer pathogenesis, Dr. Segal and colleagues treated V parvula–enriched mice with an antibody targeted to IL-17, which resulted in a significant decrease in tumor burden compared with mice treated with a control.
“Given the results of our study, it is possible that changes to the lung microbiome could be used as a biomarker to predict prognosis or to stratify patients for treatment,” said Dr. Segal. “Another exciting possibility is to target the microbiome itself or the host response to microbes as a form of cancer therapy. Our results using an antibody against IL-17 suggest that this could be an effective strategy.”
A limitation of the study was that the sample size prevented additional stratification of patients into subgroups based on the treatments they received. Additionally, since the lung microbiome was sampled only prior to treatment, changes resulting from treatment could not be assessed.
Disclosure: The study was supported by the National Institutes of Health, Foundation for the National Institutes of Health, Department of Defense, the 2018 AACR-Johnson & Johnson Lung Cancer Innovation Science Grant, A Breath of Hope Lung Foundation, Simons Foundation, Clinical and Translational Science Awards, the Cancer Center Support Grant at the Laura and Isaac Perlmutter Cancer Center, the Flight Attendant Medical Research Institute Young Clinical Scientist Award, and the Stony Wold-Herbert Fund Grant-in-Aid/Fellowship. Dr. Segal reported no conflicts of interest.